Marcela García-Villa, Clinical Neurology Service, Hospital Star Médica, Morelia, Michoacán, Mexico Raúl Leal-Cantú, Neurology Department, Hospital General “Dr. Miguel Silva,” Morelia, Michoacan, Mexico Rosa G. Madrigal-Salas, Neurology Department, Hospital General “Dr. Miguel Silva,” Morelia, Michoacan, Mexico Ildefonso Rodríguez-Leyva, Department of Neurology, Faculty of Medicine, Hospital Central Dr. Ignacio Morones Prieto, Universidad Autónoma de San Luis Potosí, SLP, Mexico Mariana A. Quintana-Díaz, Medicine and Health Scinence School, Tecnológico de Monterrey, Guadalajara, Jalisco, Mexico Conne L. Gonzalez-García, Clinical Research Unity, Hospital General “Dr. Miguel Silva,” Morelia, Michoacán, Mexico

Objective: This work is the first registry focused on knowing patients’ characteristics with Parkinson’s disease (PD), evolution and treatment used in the state of Michoacán. Methods: 68 patients with PD from the neurology consultation of the General Hospital “Dr. Miguel Silva” from October 1, 2019, to December 31, 2019, who fulfilled the UKPDSBB criteria, were studied. Sociodemographic data, disease duration, and severity according to the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) and Hoehn and Yahr Scale were collected. Results: A total of 68 patients were included in the study. Seven of them were eliminated for not meeting the inclusion criteria. Of the 61 evaluated, 31 (50.8%) were women, the mean age was 68 years (± 9.8) and the age of diagnosis was 61 years (± 12.6). The predominant comorbidities were diabetes mellitus (16.4%), systemic arterial hypertension (44.3%), and depression (70.5%). The dominant phenotype was rigid-akinetic, with absence or slight tremor in 50.8%. About 36.1% had between 5 and 10 years of suffering from the disease. 36.1% had exposure to pesticides; 31.1% had a history of head trauma. There were 24.6% smoking and 31.1% alcoholism. The drugs most used for motor manifestations were levodopa/carbidopa in 83.6% and pramipexole in 31.1 %. In part I of the MDS-UPDRS scale, the mean score was 9.8 ± 6.0; part II 14.37 ± 9.6; part III 21.22 ± 12.4 and part IV 3.2 ± 3.69. HY, I occupied 37.7%; II 26.2%; III 23%; IV 9.8% and V 3.3%. Conclusions: In this population, the disease occurred without distinction of gender. The only treatment was pharmacological. Rehabilitation, the support of the psychiatrist and nutritionists, is essential for comprehensive management.

Keywords: Parkinson’s disease. Mexico. Cross-sectional study.